184 related articles for article (PubMed ID: 31509713)
21. Treatment of Acinetobacter infections.
Michalopoulos A; Falagas ME
Expert Opin Pharmacother; 2010 Apr; 11(5):779-88. PubMed ID: 20210684
[TBL] [Abstract][Full Text] [Related]
22. Optimum treatment strategies for carbapenem-resistant Acinetobacter baumannii bacteremia.
Garnacho-Montero J; Amaya-Villar R; Ferrándiz-Millón C; Díaz-Martín A; López-Sánchez JM; Gutiérrez-Pizarraya A
Expert Rev Anti Infect Ther; 2015 Jun; 13(6):769-77. PubMed ID: 25865094
[TBL] [Abstract][Full Text] [Related]
23. Rapid killing of Acinetobacter baumannii by polymyxins is mediated by a hydroxyl radical death pathway.
Sampson TR; Liu X; Schroeder MR; Kraft CS; Burd EM; Weiss DS
Antimicrob Agents Chemother; 2012 Nov; 56(11):5642-9. PubMed ID: 22908157
[TBL] [Abstract][Full Text] [Related]
24. Epidemiology of extensive drug resistant Acinetobacter baumannii (XDRAB) at Security Forces Hospital (SFH) in Kingdom of Saudi Arabia (KSA).
Al-Obeid S; Jabri L; Al-Agamy M; Al-Omari A; Shibl A
J Chemother; 2015 Jun; 27(3):156-62. PubMed ID: 25867622
[TBL] [Abstract][Full Text] [Related]
25. [Application progress of polymyxin in bloodstream infection of drug-resistant Acinetobacter baumannii].
Zhang S; Sun L; Sun L; Yang Z
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2021 Nov; 33(11):1401-1404. PubMed ID: 34980319
[TBL] [Abstract][Full Text] [Related]
26. The Low-Alkalinity Polymyxin Derivative, AL-6, Shows High Activity Against Multidrug-Resistant
Chen DJ; Cui AL; Chen JR; Yang P; Jin J; Shao L; Li ZR
Microb Drug Resist; 2021 Jul; 27(7):933-941. PubMed ID: 33544031
[TBL] [Abstract][Full Text] [Related]
27. Trend of extensively drug-resistant Acinetobacter baumannii and the remaining therapeutic options: a multicenter study in Tehran, Iran over a 3-year period.
Jasemi S; Douraghi M; Adibhesami H; Zeraati H; Rahbar M; Boroumand MA; Aliramezani A; Ghourchian S; Mohammadzadeh M
Lett Appl Microbiol; 2016 Dec; 63(6):466-472. PubMed ID: 27626896
[TBL] [Abstract][Full Text] [Related]
28. An update on the arsenal for multidrug-resistant Acinetobacter infections: polymyxin antibiotics.
Kassamali Z; Jain R; Danziger LH
Int J Infect Dis; 2015 Jan; 30():125-32. PubMed ID: 25461655
[TBL] [Abstract][Full Text] [Related]
29. Combination therapy with polymyxin B and netropsin against clinical isolates of multidrug-resistant Acinetobacter baumannii.
Chung JH; Bhat A; Kim CJ; Yong D; Ryu CM
Sci Rep; 2016 Jun; 6():28168. PubMed ID: 27306928
[TBL] [Abstract][Full Text] [Related]
30. Polymyxin Resistance in Acinetobacter baumannii: Genetic Mutations and Transcriptomic Changes in Response to Clinically Relevant Dosage Regimens.
Cheah SE; Johnson MD; Zhu Y; Tsuji BT; Forrest A; Bulitta JB; Boyce JD; Nation RL; Li J
Sci Rep; 2016 May; 6():26233. PubMed ID: 27195897
[TBL] [Abstract][Full Text] [Related]
31. Colistin-resistant Acinetobacter baumannii: beyond carbapenem resistance.
Qureshi ZA; Hittle LE; O'Hara JA; Rivera JI; Syed A; Shields RK; Pasculle AW; Ernst RK; Doi Y
Clin Infect Dis; 2015 May; 60(9):1295-303. PubMed ID: 25632010
[TBL] [Abstract][Full Text] [Related]
32. Comparison of disc diffusion, Etest and broth microdilution for testing susceptibility of carbapenem-resistant P. aeruginosa to polymyxins.
van der Heijden IM; Levin AS; De Pedri EH; Fung L; Rossi F; Duboc G; Barone AA; Costa SF
Ann Clin Microbiol Antimicrob; 2007 Aug; 6():8. PubMed ID: 17697363
[TBL] [Abstract][Full Text] [Related]
33. High rates of resistance to colistin and polymyxin B in subgroups of Acinetobacter baumannii isolates from Korea.
Ko KS; Suh JY; Kwon KT; Jung SI; Park KH; Kang CI; Chung DR; Peck KR; Song JH
J Antimicrob Chemother; 2007 Nov; 60(5):1163-7. PubMed ID: 17761499
[TBL] [Abstract][Full Text] [Related]
34. Comparison of tigecycline susceptibility testing methods for multidrug-resistant Acinetobacter baumannii.
Idelevich EA; Freeborn DA; Seifert H; Becker K
Diagn Microbiol Infect Dis; 2018 Aug; 91(4):360-362. PubMed ID: 29778562
[TBL] [Abstract][Full Text] [Related]
35. How should we treat acinetobacter pneumonia?
Amaya-Villar R; Garnacho-Montero J
Curr Opin Crit Care; 2019 Oct; 25(5):465-472. PubMed ID: 31335380
[TBL] [Abstract][Full Text] [Related]
36. OXA-type Carbapenemases and Susceptibility of Colistin and Tigecycline Among Carbapenem-Resistant Acinetobacter Baumannii Isolates from Patients with Bacteremia in Turkey.
Cakirlar FK; Ciftci IH; Gonullu N
Clin Lab; 2015; 61(7):741-7. PubMed ID: 26299073
[TBL] [Abstract][Full Text] [Related]
37. Comparative evaluation of the VITEK 2, disk diffusion, etest, broth microdilution, and agar dilution susceptibility testing methods for colistin in clinical isolates, including heteroresistant Enterobacter cloacae and Acinetobacter baumannii strains.
Lo-Ten-Foe JR; de Smet AM; Diederen BM; Kluytmans JA; van Keulen PH
Antimicrob Agents Chemother; 2007 Oct; 51(10):3726-30. PubMed ID: 17646414
[TBL] [Abstract][Full Text] [Related]
38. Molecular characterization and antimicrobial susceptibility of Acinetobacter baumannii isolates obtained from two hospital outbreaks in Los Angeles County, California, USA.
Warner WA; Kuang SN; Hernandez R; Chong MC; Ewing PJ; Fleischer J; Meng J; Chu S; Terashita D; English L; Chen W; Xu HH
BMC Infect Dis; 2016 May; 16():194. PubMed ID: 27146090
[TBL] [Abstract][Full Text] [Related]
39. In-vitro activity of the novel fluorocycline eravacycline against carbapenem non-susceptible Acinetobacter baumannii.
Seifert H; Stefanik D; Sutcliffe JA; Higgins PG
Int J Antimicrob Agents; 2018 Jan; 51(1):62-64. PubMed ID: 28705668
[TBL] [Abstract][Full Text] [Related]
40. In vitro effects of tigecycline in combination with colistin (polymyxin E) and sulbactam against multidrug-resistant Acinetobacter baumannii.
Ni W; Cui J; Liang B; Cai Y; Bai N; Cai X; Wang R
J Antibiot (Tokyo); 2013 Dec; 66(12):705-8. PubMed ID: 23981963
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
